On Wednesday, it forecast stronger-than-expected sales and profit growth this year
Food and Drug Administration (FDA) in 2022 for the treatment of type 2 diabetes and as an adjunct to diet and exercise for weight management, GLP-1 has shown remarkable efficacy in managing blood glucose levels and promoting significant weight loss
Though GLP-1s are white-hot now, they arent the only way to shed pounds and keep them off
NHS England and NICE have proposed a 20 million threshold : if a new drug is expected to cost the NHS more than 20m per year in the first 3 years, it triggers mandatory negotiation of access schemes to manage uptake ( [23] )
doi:10.1016/j.biochi.2016.02.012 [PubMed] [Elsevier] 119
via Reuters "Investors were most encouraged by the performance of the lower 4 mg dose of retatrutide, which produced roughly 19% weight loss, comparable to the highest dose of current blockbuster therapy Zepbound." #pharmacy #GLP #healthcare To view or add a comment, sign in The most interesting part of Pfizers latest obesity data isnt the 12.3% placebo-adjusted weight loss, its the fact that it was achieved while transitioning patients to once-monthly dosing
